| Literature DB >> 3834065 |
L J Leeson, D Adair, J Clevenger, N Chiang.
Abstract
A system is described for developing extended-release products, based upon predicting or simulating the entire plasma level-time curve to be expected from the administration of a controlled-release oral dosage form. Termed "biorelevant dissolution," it employs the product's in vitro dissolution behavior and the drug's pharmacokinetic parameters in conjunction with a classical pharmacokinetic model. The basic system is described along with some pertinent examples.Mesh：
Substances：
Year: 1985 PMID： 3834065 DOI： 10.1007/bf01059332
Source DB: PubMed Journal: J Pharmacokinet Biopharm ISSN： 0090-466X